Ratio Analysis: Unpacking Biocryst Pharmaceuticals Inc. (BCRX)’s Price-to-Cash and Price-to-Free Cash Flow

Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

After finishing at $7.79 in the prior trading day, Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) closed at $7.63, down -2.05%. In other words, the price has decreased by -$2.05 from its previous closing price. On the day, 1.76 million shares were traded. BCRX stock price reached its highest trading level at $7.825 during the session, while it also had its lowest trading level at $7.57.

Ratios:

Our goal is to gain a better understanding of BCRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.78 and its Current Ratio is at 2.82.

On September 18, 2023, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform and also upped its target price recommendation from $9 to $10.

Jefferies Upgraded its Hold to Buy on August 04, 2023, while the target price for the stock was maintained at $11.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 24 ’24 when McKee Amy E sold 8,600 shares for $6.32 per share. The transaction valued at 54,352 led to the insider holds 27,831 shares of the business.

SANDERS MACHELLE sold 4,689 shares of BCRX for $28,134 on Jun 17 ’24. The Director now owns 27,742 shares after completing the transaction at $6.00 per share. On Jun 14 ’24, another insider, HEGGIE THERESA, who serves as the Director of the company, sold 6,698 shares for $6.11 each. As a result, the insider received 40,925 and left with 52,852 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCRX now has a Market Capitalization of 1578540160 and an Enterprise Value of 2157153792. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.13. Its current Enterprise Value per Revenue stands at 5.644 whereas that against EBITDA is -40.926.

Stock Price History:

Over the past 52 weeks, BCRX has reached a high of $8.88, while it has fallen to a 52-week low of $4.03. The 50-Day Moving Average of the stock is -1.87%, while the 200-Day Moving Average is calculated to be 23.05%.

Shares Statistics:

The stock has traded on average 2.38M shares per day over the past 3-months and 1815540 shares per day over the last 10 days, according to various share statistics. A total of 205.77M shares are outstanding, with a floating share count of 195.77M. Insiders hold about 5.37% of the company’s shares, while institutions hold 82.30% stake in the company. Shares short for BCRX as of 1724976000 were 24060499 with a Short Ratio of 10.09, compared to 1722384000 on 24384903. Therefore, it implies a Short% of Shares Outstanding of 24060499 and a Short% of Float of 11.72.

Most Popular